Northland analyst Carl Byrnes lowered the firm’s price target on TriSalus Life Sciences (TLSI) to $8 from $12.50 and keeps an Outperform rating on the shares. The firm is revising its FY26 and FY27 revenue estimates to reflect “a more measured, yet sustainable 30% growth trajectory,” says the analyst, who is adjusting the firm’s 12-month price target to reflect these assumptions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus: Versatile PEDD Platform, Compelling Nelitolimod Data, and Expanding TriNav Revenue Support Buy Rating
- TriSalus Life Sciences Signals Confident Growth Path
- TriSalus Life Sciences price target lowered to $7 from $12 at Canaccord
- TriSalus Life Sciences sees FY26 revenue $60M-$62M, consensus $60.34M
- TriSalus Life Sciences reports Q4 EPS (21c), consensus (14c)